The inability to predict any given individual’s unique response to psychiatric treatment is a huge bottleneck to recovery from mental health conditions. To address this challenge, we are creating a deep-learning based clinical decision tool for physicians to bring personalized medicine to psychiatry. Initially, we will be focusing on treatments for depression, but we plan to scale aifred to encompass all mental health conditions in order to amplify clinical utility. At its core, aifred is leveraging the collective intelligence of the scientific and medical community to bring better healthcare to all. We are a proud official IBM Watson AI XPrize team, headquartered in Montreal, Canada.